BridgeMD
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has progressed
EU CTIS ID: 2025-521636-10-00
What this study is testing
To assess the efficacy of RO7268489 in adults with PMS receiving ocrelizumab on disability progression
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age 18 to 60 years, inclusive, at the time of signing the Informed Consent Form
- Progressive multiple sclerosis, in accordance with the revised 2017 McDonald criteria (Thompson 2018)
- Expanded Disability Status Scale (EDSS) at Screening between 3.0 and 6.0 inclusive
- Documented evidence of disability progression independent of relapse activity over the 2 years before the screening visit, according to criteria provided in the protocol
- For patients who received ocrelizumab in the past and stopped it more than 2 years prior to screening, the reason for stopping or interrupting ocrelizumab must have been unrelated to safety / lack of efficacy and such patients must have normal B cell count at screening
- Agreement to wear digital gait assessment device as per study protocol
You likely can't join if
- MS relapse during the 6 months preceding the randomization date
- Lack of peripheral venous access
- History of alcohol or other drug abuse, in the opinion of the investigator, within 5 years prior to screening
- Inability to complete an magnetic resonance imaging (MRI)
- Contraindications to ocrelizumab mandatory pre-medications
- Treatment with intravenous immunoglobulin (IV Ig) or plasmapheresis within 12 weeks prior to screening
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- United States
- New Zealand
- Turkey
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; United States; New Zealand; Turkey; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.